Showing results (391-400 of 428) with videos related to

Sort By:
Pageof 43
Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast CancerMarco Tagliamento, Alessandra Gennari, Matteo Lambertini, et al.
Hepatology (Baltimore, Md.)|July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
The Oncologist|July 25, 2026
Effectiveness and Safety of Immunotherapy in Advanced NSCLC with Pericardial Effusions: A Global Retrospective Multicenter StudyTalal El Zarif, Sarah Abou Alaiwi, Amin H Nassar, et al.
JAMA Oncology|July 18, 2024
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D'Alessio, et al.
Hepatology (Baltimore, Md.)|December 7, 2024
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapyBernhard Scheiner, Beodeul Kang, Lorenz Balcar, et al.
Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.
Clinical Genitourinary Cancer|July 1, 2022
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial CarcinomaDimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapyAlessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
Clinical Genitourinary Cancer|September 26, 2022
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial CarcinomaRafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, et al.
Pageof 43